PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

The introduction of PD-1/PD-L1 pathway inhibitors has marked a significant milestone in the treatment of various types of solid tumors. The current situation in multiple myeloma (MM) is rather unclear, as distinct research groups have reported discordant results. This discrepancy dominantly concerns...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2016-12, Vol.5 (12), p.e1254856-e1254856
Main Authors: Jelinek, T., Hajek, R.
Format: Article
Language:English
Subjects:
Daratumumab
durvalumab
ibrutinib
irradiation
multiple myeloma
nivolumab
PD-1
PD-L1
pembrolizumab
pidilizumab
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The introduction of PD-1/PD-L1 pathway inhibitors has marked a significant milestone in the treatment of various types of solid tumors. The current situation in multiple myeloma (MM) is rather unclear, as distinct research groups have reported discordant results. This discrepancy dominantly concerns the expression of PD-1/PD-L1 molecules as well as the identification of the responsible immune effector cell population. The results of monotherapy with PD-1/PD-L1 inhibitors have been unsatisfactory in MM, suggesting that a combination approach is needed. The most logical partners are immunomodulatory agents as they possess many synergistic effects. We are also proposing other rational and promising combinations (e.g., daratumumab, ibrutinib, anti-CD137) that warrant further investigation.
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.1080/2162402X.2016.1254856